Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selcuk Ecza Deposu Ticaret venayi AS's revenue per share for the
three
months ended in Jun. 2026 was ₺86.06.
Selcuk Ecza Deposu Ticaret venayi AS's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was ₺315.36.
Warning Sign:
Selcuk Ecza Deposu Ticaret ve Sanayi AS revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Selcuk Ecza Deposu Ticaret venayi AS was 5.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 26.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 60.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 43.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
IST:SELEC'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.8 Med: 18.7 Max: 88.6
Current: 26.4
During the past 13 years, Selcuk Ecza Deposu Ticaret venayi AS's highest 3-Year average Revenue Per Share Growth Rate was 88.60% per year. The lowest was -0.80% per year. And the median was 18.70% per year.
IST:SELEC's 3-Year Revenue Growth Rate is ranked better than 89.83% of 118
companies
in the Medical Distribution industry
Industry Median: 4.55
vs IST:SELEC: 26.40
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Selcuk Ecza Deposu Ticaret venayi AS Revenue per Share Related Terms
Selcuk Ecza Deposu Ticaret venayi AS Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS Revenue per Share Chart
IST:SELEC vs MCK, COR, CAH: Revenue per Share Comparison
For the Medical Distribution subindustry, Selcuk Ecza Deposu Ticaret venayi AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selcuk Ecza Deposu Ticaret venayi AS PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Selcuk Ecza Deposu Ticaret venayi AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Selcuk Ecza Deposu Ticaret venayi AS's PS Ratio falls into.
Selcuk Ecza Deposu Ticaret venayi AS Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺315.36
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) has a Revenue per Share of ₺315.36 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. According to the industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #12 out of 118 companies in the Medical Distribution industry, placing it in the top 10.2%.
Is Selcuk Ecza Deposu Ticaret venayi AS's Revenue per Share too high?
Selcuk Ecza Deposu Ticaret venayi AS's current Revenue per Share is ₺315.36. Based on the distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #12 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Selcuk Ecza Deposu Ticaret venayi AS has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selcuk Ecza Deposu Ticaret venayi AS's Revenue per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #12 out of 118 companies for Revenue per Share. This places Selcuk Ecza Deposu Ticaret venayi AS in the top 10% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 4.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Distribution company?
The median Revenue per Share among Medical Distribution companies is 4.55, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. For the Medical Distribution industry, the median Revenue per Share is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selcuk Ecza Deposu Ticaret venayi AS's current Revenue per Share is ₺315.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selcuk Ecza Deposu Ticaret venayi AS stock overvalued right now?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺127.66, compared to a current price of ₺212.90 — trading 66.8% above its estimated fair value. The current Revenue per Share is ₺315.36. Selcuk Ecza Deposu Ticaret venayi AS's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC), the current Revenue per Share is ₺315.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Overvalued in 2026?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS stock appears to be overvalued.
The current stock price of ₺212.90 is trading 66.8% above its estimated GF Value™ of ₺127.66.
GuruFocus considers Selcuk Ecza Deposu Ticaret venayi AS to be Significantly Overvalued.
Key valuation signals for IST:SELEC:
Revenue per Share: ₺315.36
GF Value™: ₺127.66 vs. price of ₺212.90 (66.8% above fair value)
No single metric tells the full story. See the IST:SELEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
81GF Score
Get the complete analysis for IST:SELEC
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SELEC has been successfully added to your 
